Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge

Vaccine

Volumn 30, Issue 46, 2012, Pages 6541-6550

  Morello, Christopher S ^a   Kraynyak, Kimberly A ^a   Levinson, Michael S ^b   Chen, Zhijiang ^c   Lee, Kuo Fen ^c   Spector, Deborah H ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

Herpes Simplex Virus Type 2 (HSV 2); Inactivated vaccine; MPL alum; Prime boost

Indexed keywords

ALUMINUM POTASSIUM SULFATE; DNA POLYMERASE; DNA VACCINE; HELICASE; HERPES SIMPLEX VACCINE; INACTIVATED VIRUS VACCINE; PHOSPHORYL LIPID A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG RECHALLENGE; FEMALE; FEMALE GENITAL TRACT INFECTION; HERPES SIMPLEX VIRUS 2; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPINAL GANGLION; VIRUS LOAD; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIGENS, VIRAL; DISEASE MODELS, ANIMAL; FEMALE; GANGLIA, SPINAL; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HERPESVIRUS VACCINES; LIPID A; MICE; MICE, INBRED BALB C; SURVIVAL ANALYSIS; VACCINATION; VACCINES, DNA; VAGINA; VIRUS SHEDDING;

EID: 84867023587     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.08.049     Document Type: Article

References (34)

1. Xu F., Sternberg M.R., Gottlieb S.L., Berman S.M., Markowitz L.E., Forhan S.E., et al. Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years - United States, 2005-2008 2010, Centers for Disease Control and Prevention, Atlanta, GA, April 23, 2010.
2. Kimberlin D.W. Management of HSV encephalitis in adults and neonates: diagnosis, prognosis and treatment. Herpes 2007, 14(June(1)):11-16.
3. Dupuis S., Jouanguy E., Al-Hajjar S., Fieschi C., Al-Mohsen I.Z., Al-Jumaah S., et al. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat Genet 2003, 33(March(3)):388-391.
4. Freeman E.E., Weiss H.A., Glynn J.R., Cross P.L., Whitworth J.A., Hayes R.J. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006, 20(January(1)):73-83.
5. Wald A., Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002, 185(January(1)):45-52.
6. Schiffer J.T., Wald A., Selke S., Corey L., Magaret A. The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions. J Inf Dis 2011, 204(August(4)):554-561.
7. Schacker T., Zeh J., Hu H.L., Hill E., Corey L. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis 1998, 178(December(6)):1616-1622.
8. Corey L., Langenberg A.G., Ashley R., Sekulovich R.E., Izu A.E., Douglas J.M., et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. J Am Med Assoc 1999, 282(July(4)):331-340.
9. Koelle D.M., Corey L. Herpes simplex: insights on pathogenesis and possible vaccines. Annu Rev Med 2008, 59:381-395.
10. Zhu J., Koelle D.M., Cao J., Vazquez J., Huang M.L., Hladik F., et al. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 2007, 204(March(3)):595-603.
11. Koelle D.M., Posavad C.M., Barnum G.R., Johnson M.L., Frank J.M., Corey L. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest 1998, 101(April(7)):1500-1508.
12. Belshe R.B., Leone P.A., Bernstein D.I., Wald A., Levin M.J., Stapleton J.T., et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012, 366(January(1)):34-43.
13. Da Costa X., Kramer M.F., Zhu J., Brockman M.A., Knipe D.M. Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. J Virol 2000, 74(September(17)):7963-7971.
14. Da Costa X.J., Jones C.A., Knipe D.M. Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Proc Natl Acad Sci USA 1999, 96(June(12)):6994-6998.
15. Hoshino Y., Dalai S.K., Wang K., Pesnicak L., Lau T.Y., Knipe D.M., et al. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol 2005, 79(January(1)):410-418.
16. Hoshino Y., Pesnicak L., Dowdell K.C., Burbelo P.D., Knipe D.M., Straus S.E., et al. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J Infect Dis 2009, 200(October(7)):1088-1095.
17. Hoshino Y., Pesnicak L., Dowdell K.C., Lacayo J., Dudek T., Knipe D.M., et al. Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs. Vaccine 2008, 26(July(32)):4034-4040.
18. Roizman B., Knipe D.M., Whitley R.J. Herpes simplex viruses. Fields virology 2007, 2501-2601. Lippincott Williams & Wilkins, Philadelphia. 5th ed. D.M. Knipe, P.M. Howley (Eds.).
19. Morello C.S., Levinson M.S., Kraynyak K.A., Spector D.H. Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 Is highly protective against acute and recurrent HSV-2 disease. J Virol 2011, 85(April(7)):3461-3472.
20. Parr M.B., Kepple L., McDermott M.R., Drew M.D., Bozzola J.J., Parr E.L. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Lab Invest 1994, 70(March(3)):369-380.
21. Dudek T., Mathews L.C., Knipe D.M. Disruption of the U(L)41 gene in the herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes. Virology 2008, 372(March(1)):165-175.
22. Kwissa M., Lindblad E.B., Schirmbeck R., Reimann J. Codelivery of a DNA vaccine and a protein vaccine with aluminum phosphate stimulates a potent and multivalent immune response. J Mol Med 2003, 81(August(8)):502-510.
23. Cook I.F., Barr I., Hartel G., Pond D., Hampson A.W. Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults. Vaccine 2006, 24(March(13)):2395-2402.
24. Mark A., Carlsson R.M., Granstrom M. Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents. Vaccine 1999, 17(April(15-16)):2067-2072.
25. Pittman P.R. Aluminum-containing vaccine associated adverse events: role of route of administration and gender. Vaccine 2002, 20(May(Suppl. 3)):S48-S50.
26. Ruben F.L., Froeschle J.E., Meschievitz C., Chen K., George J., Reeves-Hoche M.K., et al. Choosing a route of administration for quadrivalent meningococcal polysaccharide vaccine: intramuscular versus subcutaneous. Clin Infect Dis 2001, 32(January(1)):170-172.
27. Khodai T., Chappell D., Christy C., Cockle P., Eyles J., Hammond D., et al. Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models. Clin Vaccine Immun 2011, 18(October(10)):1702-1709.
28. McKendall R.R., Woo W. Murine IgG subclass responses to herpes simplex virus type 1 and polypeptides. J Gen Virol 1988, 69(April(Pt 4)):847-857.
29. Sin J.I., Bagarazzi M., Pachuk C., Weiner D.B. DNA priming-protein boosting enhances both antigen-specific antibody and Th1-type cellular immune responses in a murine herpes simplex virus-2 gD vaccine model. DNA Cell Biol 1999, 18(October(10)):771-779.
30. Ishizaka S.T., Piacente P., Silva J., Mishkin E.M. IgG subtype is correlated with efficiency of passive protection and effector function of anti-herpes simplex virus glycoprotein D monoclonal antibodies. J Infect Dis 1995, 172(October(4)):1108-1111.
31. Dudek T.E., Torres-Lopez E., Crumpacker C., Knipe D.M. Evidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa. J Infect Dis 2011, 203(May(10)):1434-1441.
32. Awasthi S., Lubinski J.M., Shaw C.E., Barrett S.M., Cai M., Wang F., et al. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone. J Virol 2011, 85(October(20)):10472-10486.
33. Awasthi S., Zumbrun E.E., Si H., Wang F., Shaw C.E., Cai M., et al. Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread. J Virol 2012, 86(April(8)):4586-4598.
34. Halford W.P., Puschel R., Gershburg E., Wilber A., Gershburg S., Rakowski B. A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. PLoS One 2011, 6(3):e17748.